BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, January 12, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

June 15, 2021

View Archived Issues
Illustration of stent angioplasty balloon in artery

New study of paclitaxel devices reverses narrative regarding mortality

The controversy over the use of paclitaxel in devices for the peripheral vasculature has taken a significant bite out of sales, but a new study serves to help reverse the narrative regarding mortality. According to a study of more than 168,000 Medicare patients, stents and angioplasty balloons coated with paclitaxel (PTX) were non-inferior to non-coated devices for mortality out to nearly three years, a finding that may encourage clinicians to return to normal utilization patterns and thus help to restore sales volumes. Read More
NIVAHF device image

Volumetrix wins breakthrough nod for heart failure monitoring solution

The FDA granted breakthrough device designation to Volumetrix LLC for its NIVAHF monitoring system for heart failure. The device is the first application of the company’s noninvasive venous waveform analysis (NIVA) technology, which captures and analyzes vital information about blood volume to assess patient status. Read More
G7 flags

G7 not wavering in support for voluntary licensing

Noticeably lacking in the G7 communique following its recent U.K. summit is support for a proposed World Trade Organization waiver on intellectual property related to drugs and other medical products used to prevent, contain or treat COVID-19 infections. Read More
3d-printing.png

New 3D printing process to tailor-make medical devices combats bacterial resistance

A new 3D printing technique has allowed University of Nottingham researchers to tailor-make artificial body parts and other medical devices that are both implantable and bacteria-resistant. The multi-materials manufactured in the study were also adapted to 3D printing technology that is able to offer devices that can better meet the need of the patient and minimize the surgeries led by device failure that increase the risk of infections. Read More
Acqmap console image

Acutus rings up regulatory approvals

Acutus Medical Inc. scored big with regulators in recent weeks. The company, which focuses on devices to diagnose and treat cardiac arrhythmias, received FDA approval to launch an investigational device exemption clinical trial for its Acqblate Force sensing ablation catheter and system in atrial fibrillation just two weeks after gaining CE mark approval for a broad suite of electrophysiology products. Read More
Deal-merger-money-lightbulb.png

Titan takes off with $10M Medtronic license payment

TORONTO – Titan Medical Inc. has received a $10 million license payment from Medtronic plc for a total of $30 million that the Irish med-tech firm has invested in robotic-assisted surgical technologies developed by Titan. Titan is pursuing gynecologic surgical applications for its Enos robotic single access surgical system, licensing it and related intellectual property to Medtronic while retaining worldwide rights to commercialize technologies for use with the Enos system. Read More

Appointments and advancements for June 15, 2021

New hires and promotions in the med-tech industry, including: Adapthealth, Atricure, Augmedix, Deepcell, Edap Tms, Endra, Helius Medical Technologies, One Drop, Ortho Regenerative Technologies, Quil, Stentit, Talkspace. Read More

Financings for June 15, 2021

Med-tech firms raising money in public or private financings, including: Surgalign. Read More

In the clinic for June 15, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Attralus, Bioprotect, Novadip, Proven Pharmaceuticals. Read More

Other news to note for June 15, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 221b Foundation, Agilon Health, Albot, BBI Group, Biodesix, BGI Americas, Champions Oncology, Cloudbreak Health, Confluent Medical Technologies, Echelon Diagnostics, Elidah, Genetic Analysis, Genscript, Healthcare Triangle, Icare, Leadingreach, Mellingmedical, Neurometrix, Novo Holdings, Oncocyte, Personal Genome Diagnostics, Physiq, Sherlock Biosciences, Trialbee, Umotif, Uphealth, Vntc. Read More

Regulatory actions for June 15, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Kheiron Medical Technologies, Letsgetchecked, Liquiglide, Livanova. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 9, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • LINC01116 has prognostic value in lung cancer, study shows

    BioWorld Science
    Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
  • Icons representing scientific research

    Science in 2025: the best of the rest

    BioWorld Science
    A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing